Skip to main content
PLOS One logoLink to PLOS One
. 2023 Jun 6;18(6):e0286634. doi: 10.1371/journal.pone.0286634

Psychometric properties of the Generalised Anxiety Disorder Dimensional Scale in an Australian sample

David Groves 1, Theodora Binasis 1, Bethany Wootton 2, Karen Moses 1,*
Editor: Alejandro Vega-Muñoz3
PMCID: PMC10243613  PMID: 37279207

Abstract

The Generalised Anxiety Disorder Dimensional Scale is a new measure of generalised anxiety disorder developed to assist clinicians in the dimensional assessment of generalised anxiety disorder by the Diagnostic and Statistical Manual (Fifth Edition) Anxiety, Obsessive-Compulsive Spectrum, Posttraumatic, and Dissociative Disorder Work Group. This study aims to evaluate the psychometric properties of the scale in an Australian community sample. A sample of 293 Australians (72.7% female) aged between 18 and 73 (M = 28.31 years; SD = 12.11 years) was recruited. Participants completed the Generalised Anxiety Disorder Dimensional Scale, as well as related measures used to assess convergent and discriminant validity. A small proportion of the sample (n = 21) completed the scale a second time to assess test-retest reliability. The scale demonstrated a unidimensional factor structure, good internal consistency (Cronbach’s α = .94), good test-retest reliability (ICC = .85), good convergent validity with the Generalised Anxiety Disorder– 7 item (rs = .77), and discriminant validity with the Panic Disorder Severity Scale–Self Report (rs = .63). The scale appears to be a reliable and valid measure of generalised anxiety disorder symptomology for use in the Australian population.

1. Introduction

Generalised anxiety disorder (GAD) is characterised by worry and/or anxiety about multiple activities or events that is excessive and difficult to control [1]. International epidemiological research estimated that GAD has lifetime prevalence of 3.7% and 12-month prevalence of 1.8% [2]. In comparison, the Australian population has been found to have a higher than average rate of GAD, both in one-year prevalence (3.6%) and lifetime prevalence (8%) [2]. The disorder is associated with reduced quality of life [3] and imposes a significant burden [4].

Fortunately, effective treatments for GAD exist, which are best utilized after an evidence-based clinical assessment [5]. Self-report measures are considered to be a key component of this evidence-based assessment and provide a number of benefits, including that they can be used to inform diagnosis [6] and monitor symptom change over time [7]. Whilst the prevailing diagnostic approach has been the categorical classification of mental disorder, the DSM-5 introduced a supplemental dimensional approach. A dimensional approach to disorder classification allows for a better assessment of patterns, severity and number of symptoms experienced [8].

The DSM-5 Anxiety, Obsessive-Compulsive Spectrum, Posttraumatic, and Dissociative Disorder Work Group developed dimensional scales for the DSM-5 anxiety disorders [9]. Using a common, 10-item template, these scales assess the constructs of fear and anxiety that are shared–but manifest differently–across each of the disorders [10]. To date, the psychometric properties of the Dimensional Anxiety Scales have been examined in clinical and community samples in the USA [9], Germany [10, 11], the Netherlands [12, 13], and Brazil [14]. However, no studies have examined the properties of the dimensional anxiety scales in an Australian sample. Furthermore, only one of the studies mentioned above was conducted using the English version of the scales [9]; in other studies, the scales were translated into German, Dutch, and Portuguese-Brazilian.

Across studies, the Generalised Anxiety Disorder Dimensional Scale (GAD-D) has been found to have a unidimensional structure [10, 11, 14], good-to-excellent internal consistency [912, 14] and adequate test-retest reliability (intraclass correlation coefficients between 0.54 and 0.70; [18, 23]). Correlations of the GAD-D with measures of similar and different constructs have provided support for both convergent [15] and divergent validity [911]. Finally, DeSousa et al. [14] separated their sample into male and female populations and found good internal consistency for each, indicating that reliability was not affected by participant gender.

Taken together, research suggests that the GAD-D is a valid and reliable measure of GAD severity, that it is a freely available, brief and easy to administer. Despite research undertaken to date, there a number of gaps within the existing literature which are important to address. Firstly, an evaluation within an Australian sample is currently lacking. Secondly, only one study has examined the psychometric properties of the English version [9]. Thirdly, studies conducted to date have largely been homogenous in sample characteristics [9, 11]. Fourthly, studies have not uniformly tested each psychometric properties of the GAD-D. For example, only Beesdo-Baum et al. [10] and DeSousa et al. [14] established unidimensionality for the scale. Consequently, the factor structure of the English version of the GAD-D has not yet been examined. Finally, test-retest reliability was only assessed in American [9], Brazilian [14], and German [11] samples, and as mentioned above, these studies yielded varying results. Given the above, the generalizability of the GAD-D, particularly within the general population and the Australian context more broadly, remains unknown. Given that the prevalence [2] and expression [16] of GAD-D varies across countries, an evaluation within other cultures, including the Australian context is warranted.

The present study aims to measure the psychometric properties of the GAD-D in a community sample of Australian adults. Establishing these psychometric properties using an Australian sample would give clinicians working in Australia an empirical basis for using this scale to screen for, measure, and monitor GAD symptomology and severity in the populations they work with and will also add to the growing literature demonstrating the psychometric properties of the DSM-5 dimensional scales in the Australian population [1720]. The following were investigated: 1) factor structure; 2) reliability; and 3) convergent and discriminant validity. It was hypothesised that the psychometric properties of this scale will be consistent with previous evaluations [9, 10, 12, 14]. Specifically, the GAD-D is expected to demonstrate a unidimensional factor structure, excellent internal consistency, good test-retest reliability, convergent and discriminant validity.

2. Methods

2.1. Participants

A total of 355 participants commenced this study. Participants who met exclusion criteria or provided incomplete data were removed from all analyses. Two hundred and ninety-three Australian adults (M = 28.31 years; SD = 12.11 years) were included in the final sample. The sample was predominantly female (72.7%). To be included in this study, participants were required to 1) be aged 18 years or over, 2) live in Australia, and 3) be fluent in English. Further sample characteristics are presented in Table 1. As this study utilized a non-clinical community sample, psychiatric history was not sought from participants. Ethical approval was granted by the Western Sydney University Human Research Ethics Committee.

Table 1. Participant characteristics (N = 293).

Variable n %
Gender (% female) 213 72.7
Marital Status
    Single 186 63.5
    Married 53 18.1
    De Facto 38 13.0
    Divorced 11 3.8
    Widowed 1 0.3
    Separated 4 1.4
Employment Status
    Working part time 83 28.3
    Working full time 80 27.3
    Unemployed 13 4.4
    Studying 101 34.5
    Retired 2 0.7
    Full time carer 2 0.7
    Other 12 4.1
Highest Education Level
    School Certificate 29 9.9
    Trade Certificate 17 5.8
    Higher School Certificate 140 47.8
    Bachelor Degree 59 20.1
    Postgraduate Degree 41 14.0
    Doctorate 7 2.4
Country of Origin
    Australia 226 77.1
    New Zealand 2 0.7
    Asia 11 3.8
    Europe 4 1.4
    United Kingdom 7 2.4
    North American 2 0.7
    South American 2 0.7
    Middle East 11 3.8
    Africa 3 1.0
    Other 25 8.5

2.2. Measures

2.2.1. Generalised Anxiety Disorder Dimensional Scale

The Generalised Anxiety Disorder Dimensional Scale (GAD-D) [9]) is a 10-item measure that assesses the frequency of symptoms relating to fear, anxiety, and worry, as well as the frequency of behaviours intended to avoid worry and escape feared situations. All items are rated on a 5-point Likert scale ranging from zero (never) to four (all of the time), resulting in a total score ranging between 0 and 40. Previous studies have established excellent internal reliability for the scale (α = .92; [9]).

2.2.2. Generalised Anxiety Disorder Scale– 7 item

The Generalised Anxiety Disorder Scale– 7 item (GAD-7) [21], is a scale measuring GAD symptomology. Participants rate the frequency with which they experienced seven symptoms of GAD during the past two weeks, on a 4-point Likert scale ranging from 0 (not at all) to 3 (nearly every day). Total scores range between 0 and 21. A score of 10 or more on the GAD-7 was established as the cut-point with an optimal balance of sensitivity (89%) and specificity (82%). Good internal reliability has been established in previous studies (α = .88) [22]. Cronbach’s α in the present study was .91.

2.2.3. Panic Disorder Severity Scale–Self Report Version

The Panic Disorder Severity Scale–Self Report Version (PDSS-SR) [23] is a seven item measure that assesses the frequency of panic attacks, anxiety, and avoidance. Participants rate the severity of panic disorder symptoms on a scale from 0 (none) to 4 (extreme), resulting in a total score ranging from 0 to 28. Houck et al. [23] demonstrated excellent internal reliability for the scale, Cronbach’s α = .91. Cronbach’s α in the present study was .92.

2.3. Procedure

Data was collected within a larger research study. Participants were recruited via social media, advertisements on community noticeboards and via email. Recruitment source was not monitored in this study. Part 1 consisted of an online questionnaire, that took approximately 20 minutes to complete. Participants viewed an information sheet and consent form, before moving on to a demographic questionnaire, the GAD-D, the GAD-7, and the PDSS-SR. Upon completion of Part 1, participants were invited to participate in Part 2 of this study to assess test-retest reliability of the GAD-D. Those who agreed were asked to input an anonymous, unique identification code to link their response from Part 1 to Part 2. Those participants were emailed by the researchers two weeks after completing Part 1, inviting them to complete the measures again. Part 2 of this study was requested to be undertaken with a two-week time interval. All data was collected via Qualtrics. Data is available from the lead investigator upon reasonable request.

2.4. Statistical analysis

Statistical analyses were conducted using IBM SPSS version 26 for Mac and R version 4.02 for Mac. To determine whether the GAD-D demonstrates a unidimensional factor structure, confirmatory factor analysis (CFA) was conducted using the R package “lavaan” version 0.6–7 [24]. The use of this analysis is consistent with that used in the existing literature [16, 17, 30, 31]. The weighted least squares means and variance adjusted (WLSMV) estimation method was used; this method does not assume that variables are normally distributed, and is considered the best option for ordinal data [25]. The following fit-indices were calculated: comparative fit index (CFI), Tucker-Lewis index (TLI), and root mean square error of approximation (RMSEA). A CFI and TLI value of 0.90 or higher is considered an acceptable fit, and 0.95 or higher is considered a good fit [26]. A RMSEA value of 0.08 or less is considered an acceptable fit, and lower than 0.05 is considered a good fit [26]. To evaluate internal consistency, Cronbach’s α was calculated for the GAD-D. Convergent validity was examined by calculating Spearman’s rank order correlation (rs) between the total score on the GAD-D and the GAD-7. Consistent with previous studies of the DSM-5 dimensional anxiety scales [9, 10], discriminant validity was defined as being demonstrated by a significantly greater correlation between the GAD-D and a previously validated measure of the same construct than between the GAD-D and a previously validated measure of a distinct construct. Discriminant validity was examined by comparing rs values of the GAD-D and GAD-7 with rs values between the GAD-D and the PDSS-SR, a conceptually distinct measure. Correlations were compared using Steiger’s [27] modification of Dunn and Clark’s [28] z using average correlations, available within the R package cocor version 1.1–3 [29]. Strength of correlation coefficient effect sizes were interpreted according to Cohen [30], where .10 is “small,” .30 is “medium,” and .50 and above is “large.” Test-retest reliability was evaluated by calculating the intra-class correlational coefficient (ICC) between total score on the GAD-D at Part 1 and Part 2. A two-way mixed effects model with absolute agreement was used to calculate the ICC [31]. Consistent with previous studies of the DSM-5 dimensional anxiety scales, an ICC above .70 was considered adequate [9]. Power analysis indicates that with a medium effect size, alpha of .05 and power of .80, 181 participants were required to assess factor analysis [32]. This figure is also consistent with Consensus-based standards for the selection of health measurement instruments guidelines [33], thus the current study was adequately powered for the factor analysis. According to Bujan and Baharum [34], with two observations per participant, an ICC greater than 0.5, an α of 0.05, and power of 0.80, 22 participants are required to estimate the value of ICC for test-retest reliability.

3. Results

3.1. Missing data

Missing data across the variables ranged from 3.3% to 21.2%. Little’s MCAR test, designed to test for patterns in missing data, indicated that the data was missing completely at random, χ2(720) = 678.01, p = .87. Listwise deletion of cases with missing data is appropriate where data is missing completely at random and adequate power is retained [35]. As the data were missing completely at random, 61 participants with missing data and one participant that was identified by the researchers as having completed the questionnaires twice were excluded from further analysis.

3.2. Assumption testing

Assumptions of normality, linearity, and homoscedasticity were assessed. Visual inspection of histograms indicated that each of the variables of interest deviated significantly from normal distribution, with each demonstrating positive skew. No outliers (operationalised as > 3.29 standard deviations above the mean) were detected for scores on the GAD-D or GAD-7. However, three outliers were identified on the PDSS-SR. To reduce bias introduced by these outliers and the positive skew on each variable, Spearman’s rank-order coefficient was used when calculating correlations, and the WLSMV estimation method was used to conduct CFA.

3.3. Descriptive statistics

Descriptive statistics for the sample are reported in Table 2. Of the 293 participants included in Part 1, 137 (46.76%) participants scored 0–10 on the GAD-D, 102 (34.81%) scored 11–20, 40 (13.65%) scored 21–30, and 14 (4.78%) scored 31–40.

Table 2. Descriptive statistics for the measures (N = 293).

Measure M (SD) Observed range Possible range
GAD-D 12.60 (9.26) 0–40 0–40
GAD-7 8.06 (5.43) 0–21 0–21
PDSS-SR 3.71 (4.61) 0–24 0–28

Note. GAD-D = Generalised Anxiety Disorder Dimensional Scale; GAD-7 = Generalised Anxiety Disorder Scale– 7 Item; PDSS-SR = Panic Disorder Severity Scale–Self Report.

3.4. Attrition

At the conclusion of Part 1, 140 (48%) individuals expressed interest in completing Part 2 of the study. Of these, 21 participants provided complete data for Part 2, after one email follow-up. These participants did not differ from those who completed only Part 1 in terms of gender (χ2[2, N = 293] = 0.67, p > .05) or level of education (χ2[5, N = 293] = 1.88, p > .05). The two groups did not differ significantly on GAD-D scores, t(25.488) = 0.87, p > .05.

3.5. Factor structure

The results of the CFA are shown in Table 3. The CFI, TLI, and RMSEA fell below the acceptable threshold, indicating a poor fit for the single factor model. Post-hoc inspection of modification indices revealed a strong local dependency between items 6 and 7. Another CFA was conducted, including the correlation between errors of items 6 and 7 in the model. The CFI, TLI, and RMSEA were all acceptable (see Table 3). The correlation coefficient of the local dependency estimates between the errors of items 6 and 7 was 0.31 (p < .001). The unstandardized and standardised regression weights for each item in the best-fit model are shown in Table 4. Correlation coefficients between each of the GAD-D items are shown in Table 5.

Table 3. Results of confirmatory factor analysis.

Instrument χ2 (df) CFI TLI RMSEA (90% CI)
CFA
GAD-D 116.441 (35),
p < .001
0.895 0.865 0.089
(0.072–0.107)
CFA (local dependency items 6 and 7)
GAD-D 90.133(34),
p < .001
0.927 0.904 0.075
(0.057–0.094)

Note. CFA = Confirmatory Factor Analysis; CFI = Comparative Fit Index, TLI = Tucker Lewis Index; RMSEA = Root Mean Square Error of Approximation; GAD-D = Generalised Anxiety Disorder Dimensional Scale.

Table 4. Confirmatory factor analysis factor loadings for GAD-D items (N = 293).

Item Unstandardised Standardised p-value Squared multiple correlations
Item 1 1.00 0.81 < .001 0.66
Item 2 0.92 0.81 < .001 0.65
Item 3 0.97 0.78 < .001 0.60
Item 4 0.90 0.81 < .001 0.65
Item 5 0.97 0.82 < .001 0.67
Item 6 0.97 0.79 < .001 0.62
Item 7 0.93 0.75 < .001 0.57
Item 8 1.08 0.83 < .001 0.69
Item 9 0.88 0.65 < .001 0.43
Item 10 0.73 0.62 < .001 0.38

Note. GAD-D = Generalised Anxiety Disorder Dimensional Scale

Table 5. Spearman rank-order correlations between GAD-D items (N = 293).

Item 1 2 3 4 5 6 7 8 9 10
1 -
2 .66 -
3 .67 .63 -
4 .64 .62 .60 -
5 .61 .69 .58 .70 -
6 .61 .57 .57 .63 .59 -
7 .59 .51 .54 .62 .56 .79 -
8 .61 .66 .58 .62 .66 .71 .69 -
9 .45 .55 .48 .43 .53 .50 .45 .60 -
10 .45 .39 .41 .50 .46 .43 .50 .46 .51 -

Note. All correlations significant at p < .001.

3.6. Reliability

Cronbach’s α for the GAD-D was .94 at Part 1 and .91 at Part 2. These results indicate excellent internal consistency. The ICC between GAD-D scores at Part 1 and Part 2 was .85 (p < .001; 95% CI = .66-.94). This strong, positive correlation indicates good test-retest reliability.

3.7. Validity

A strong, positive correlation was found between the GAD-D and GAD-7, rs = .77 (p < .001), indicating convergent validity. A strong, positive correlation was also found between the GAD-D and PDSS-SR, rs = .63 (p < .001). These correlations were compared using Steiger’s (1980) method for comparing elements of a correlation matrix. The correlation between the GAD-D and GAD-7 was significantly greater than the correlation between the GAD-D and PDSS-SR, z(290) = 4.79 (p < .001, two-tailed), providing evidence for discriminant validity.

4. Discussion

The GAD-D is a dimensional measure of GAD symptom severity recently developed by the DSM-5 Anxiety, Obsessive-Compulsive Spectrum, Posttraumatic, and Dissociative Disorder Work Group. The scale is quick to administer and purports to provide a dimensional assessment of GAD as an alternative to the prevailing categorical approach. The aim of the present study was to evaluate the psychometric properties of the scale in an Australian community sample. The GAD-D was found to have a unidimensional factor structure, excellent internal consistency, and acceptable test-retest reliability. Convergent and discriminant validity were demonstrated.

Results of the study suggest that the GAD-D has a unidimensional factor structure, consistent with previous examinations of the scale’s dimensionality [10, 14]. This indicates that the items of the GAD-D measure one underlying construct, i.e., the severity of GAD symptomology. The present study is the first to use the English language version of the GAD-D to examine its factor structure. However, the fit indices indicated only an adequate model fit. A larger sample may have resulted in better model fit, as was observed in previous studies of the GAD-D that utilised CFA [10, 14].

Consistent with the findings of DeSousa et al. [14] in their Brazilian sample, model fit was notably improved when the local dependency between items 6 and 7 was included in the model. Item 6 refers to avoiding situations about which the individual worries, while item 7 refers to leaving or participating minimally in situations about which the individual worries. In the present study, the correlation between these two items was the largest correlation found between any two GAD-D items. Of the most prevalent DSM-5 anxiety disorders (including social phobia, specific phobia, panic disorder, and agoraphobia), GAD is unique in that avoidance behaviour is not included as a criterion for diagnosis. However, the loading of these two items on the general factor were comparable to the other items on the GAD-D. This may suggest that avoidance and escape behaviours are typically observed in individuals that have GAD, despite their exclusion from the DSM-5 criteria. This would align particularly with models of GAD that highlight the maintaining role of avoidance; for example, those proposed by Borkovec [16] and Dugas et al. [36]. Future research may wish to further explore this.

Notably, although all items demonstrated adequate factor loadings in the present study, items 9 and 10 had a lower loading onto the general factor than the other items of the scale. These items refer to [9] seeking reassurance from others due to worries, and [10] needing help to cope with worries from alcohol, medication, superstitious objects, or other people. This result was inconsistent with the factor loadings reported by DeSousa et al.[14] in their Brazilian sample. One reason for this may be a cultural difference between Australians and Brazilians: Australians are perhaps typically more individualistic than Brazilians [37] and therefore less likely to seek reassurance from others or enlist their help to cope with worries. However, there is little other data to support this theory, as only two studies conducted CFA on the GAD-D, one of which did not report factor loadings [10]. Therefore, it is difficult to draw conclusions about why this pattern emerged. Researchers validating the GAD-D in the future should conduct CFA where sample size allows, providing factor loadings for each item.

Consistent with previous studies [9, 11, 12], good internal consistency was found for the GAD-D in both the original sample and in the test-retest condition. The test-retest reliability of the scale was also acceptable, indicated by a strong, positive ICC between GAD-D scores at Part 1 and Part 2. This replicates in an Australian sample the results reported by Knappe et al. [11] and LeBeau et al. [9]. Like these two studies, participants completing the GAD-D were asked to report GAD symptoms over the past month. DeSousa et al. [14] asked participants to report symptoms over the past week and found an ICC below the .70 threshold for acceptable test-retest reliability. Notably, the current publicly available version of the GAD-D also asks the individual to report symptoms over the past week. The present study contributes further evidence that the “past month” version of the scale is more reliable across time. Clinicians using the currently available version of the GAD-D to monitor symptoms on a regular basis should consider these results, noting that fluctuations of symptoms in any one week may not be indicative of overall GAD symptomology; GAD currently requires a history of six months of symptoms experienced more days than not for diagnosis [1].

Convergent validity was established by a strong, positive correlation between the GAD-D and the GAD-7, a widely used screening tool for GAD with an established cut-point for diagnosis [21]. This finding was consistent with all previous evaluations of the GAD-D. Due to this high correlation, future studies may consider the incremental validity of the measure, given that the GAD-D is three items longer than the GAD-7. The advantage of the GAD-D may instead lie in its format, which is consistent with the other DSM-5 dimensional anxiety scales, allowing a diagnostic profile to be constructed across anxiety disorders. Importantly, the GAD-D includes measures of avoidance and escape behaviours, which are typically observed in GAD but not included in the GAD-7 or the DSM-5 criteria. As avoidance is widely considered a perpetuating factor in GAD [16, 36], the GAD-D may provide incrementally more salient information to clinicians than the GAD-7.

Discriminant validity was established by comparing the correlation between the GAD-D and GAD-7 with the correlation between the GAD-D and a measure of panic disorder symptomology, the PDSS-SR. While both correlations were large and positive, the GAD-D and GAD-7 demonstrated a significantly greater correlation, consistent with LeBeau et al. [9]. This result indicates a large degree of overlap and comorbidity between GAD and panic disorder, a trend observed across anxiety disorders [38]. Therefore, future studies should test the specificity and sensitivity of the GAD-D to ensure that diagnosis is not too broadly applied.

One advantage of the present study is that the full range of response severity was observed with at least one participant having the minimum and maximum possible score on the GAD-D and GAD-7. This indicates that the sample likely included individuals with GAD and other anxiety disorders, as well as subclinical and healthy individuals from the community. The sample was also broad in terms of marital status, employment status, and highest education level. Further, 27.3% of participants were born overseas, approximately consistent with the Australian Bureau of Statistics [39] report stating that 29.7% of the Australian population were born overseas.

Several limitations of the present study should be considered. First, only a small percentage of participants (7.12%) completed Part 2 of the study. This is likely due to only one follow up email being sent to participants who expressed interest in completing this part of the study. Whilst close to recommended sample size for test re-test reliability, this small sample size may limit the generalisability of the test-retest reliability found in the present study and findings should be considered preliminary. Importantly though, other studies that have examined test-retest reliability of the GAD-D have found similar results [9, 11]. Further, the time between completion of Part 1 and Part 2 for test-retest was not strictly adhered to by participants. Future studies aiming to achieve greater generalisability should restrict or control for time elapsed between Part 1 and Part 2 for each participant. It is possible that individuals who completed Part 2 were more invested in the content of the study and may represent a distinct population compared to the overall sample. To prevent this, it may also help to provide a monetary incentive for individuals to complete both parts. Future research may also wish to use more follow up emails to increase participation in Part 2.

Although a full range of responses were recorded for each GAD measure, mean scores on the GAD-D were elevated in comparison to those reported in other studies. A similar pattern was observed regarding scores on the GAD-7 and PDSS-SR where these were utilised [9, 14]. For example, while the present study had a mean of 12.60 (SD = 9.26) on the GAD-D, the sample of German treatment-seeking individuals had a mean of 11.8 (SD = 9.9), indicating that the present community sample had a similar or even greater level of GAD or other anxiety symptomology than a sample of treatment-seeking individuals. Other studies of community samples reported lower mean scores on the GAD-D [9, 14]. While this may be in line with the elevated rates of GAD in the Australian community [2], it is possible that the study attracted a population affected by anxiety and thus especially concerned with research in this area. This effect may have been further exacerbated by the predominantly female sample, as females are more likely on average to experience GAD [40]. These factors may have led to a sample that was not representative of the Australian community.

A further limitation regards the validity of responses, given the extreme scores endorsed by a small percentage of participants on the measures of interest. In the present study, a small number of individuals endorsed items resulting in a maximum score on one or more measures. While visual inspection of overall scores did not reveal a pattern of repetitive responding across all items for any of the study participants, the incorporation of attention check items would allow for a more comprehensive assessment of this possibility. Fortunately, in the present study, the presence of extreme scores is unlikely to have affected any of the key findings, as non-parametric methods were used to calculate correlation coefficients, and the CFA estimation method chosen is known to be robust against outliers and violation of normality [26].

Overall, the present study replicates the small but growing body of literature suggesting that the GAD-D is a reliable and valid measure and is therefore appropriate for use in establishing baseline severity and monitoring GAD symptomology in the Australian population. Future research should analyse the sensitivity and specificity of the GAD-D in an Australian sample to establish a cut-off point and allow Australian clinicians to also use the GAD-D as a screening tool, using a clinical sample of individuals who have received diagnosis via structured interview. Finally, future research should aim to establish the psychometric properties of the other DSM-5 dimensional anxiety scales. If shown to be valid and reliable, the scales given as a battery would offer an efficient and consistent way for clinicians to profile individuals across anxiety disorders, potentially leading to more appropriately targeted treatment.

Supporting information

S1 File. Key statistical output.

(DOCX)

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.American Psychiatric Association %J American Psychiatric Association: Washington D, USA. Diagnostic and Statistical Manual of Mental Disorders Fifth Edition Text Revision—DSM-5-TR. 2022. [Google Scholar]
  • 2.Ruscio AM, Hallion LS, Lim CC, Aguilar-Gaxiola S, Al-Hamzawi A, Alonso J, et al. Cross-sectional comparison of the epidemiology of DSM-5 generalized anxiety disorder across the globe. 2017;74(5):465–75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Hohls JK, König H-H, Quirke E, Hajek AJIjoer, health p. Anxiety, depression and quality of life—a systematic review of evidence from longitudinal observational studies. 2021;18(22):12022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Ciobanu LG, Ferrari AJ, Erskine HE, Santomauro DF, Charlson FJ, Leung J, et al. The prevalence and burden of mental and substance use disorders in Australia: findings from the Global Burden of Disease Study 2015. 2018;52(5):483–90. [DOI] [PubMed] [Google Scholar]
  • 5.Moses K, Gayed M, Chuah S, Wootton BMJJoad. The use of evidence-based assessment for anxiety disorders in an Australian sample. 2020;75:102279. [DOI] [PubMed] [Google Scholar]
  • 6.Suhr JA. Psychological assessment: A problem-solving approach: Guilford Publications; 2015. [Google Scholar]
  • 7.Hunsley J, Mash EJ. The role of assessment in evidence‑based practice. 2020. [Google Scholar]
  • 8.Helzer JE, Kraemer HC, Krueger RFJPm. The feasibility and need for dimensional psychiatric diagnoses. 2006;36(12):1671–80. [DOI] [PubMed] [Google Scholar]
  • 9.Lebeau RT, Glenn DE, Hanover LN, Beesdo‐Baum K, Wittchen HU, Craske MGJIJoMiPR. A dimensional approach to measuring anxiety for DSM‐5. 2012;21(4):258–72. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Beesdo‐Baum K, Klotsche J, Knappe S, Craske MG, LeBeau RT, Hoyer J, et al. Psychometric properties of the dimensional anxiety scales for DSM‐V in an unselected sample of German treatment seeking patients. 2012;29(12):1014–24. [DOI] [PubMed] [Google Scholar]
  • 11.Knappe S, Klotsche J, Heyde F, Hiob S, Siegert J, Hoyer J, et al. Test–retest reliability and sensitivity to change of the dimensional anxiety scales for DSM-5. 2014;19(3):256–67. [DOI] [PubMed] [Google Scholar]
  • 12.Möller EL, Bögels SMJIJoMiPR. The DSM‐5 Dimensional Anxiety Scales in a Dutch non‐clinical sample: psychometric properties including the adult separation anxiety disorder scale. 2016;25(3):232–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Möller EL, Majdandžić M, Craske MG, Bögels SM. Dimensional assessment of anxiety disorders in parents and children for DSM‐5. International Journal of Methods in Psychiatric Research. 2014;23(3):331–44. doi: 10.1002/mpr.1450 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.DeSousa DA, Moreno AL, Osório FL, Crippa JAS, LeBeau R, Manfro GG, et al. Psychometric properties of the dimensional anxiety scales for DSM‐5 in a Brazilian community sample. 2017;26(3):e1531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.LeBeau R, Bögels S, Möller E, Craske MJPR. Integrating dimensional assessment and categorical diagnosis in DSM-5: The benefits and challenges of the paradigm shift for the anxiety disorders. 2015;2(1):83–99. [Google Scholar]
  • 16.Borkovec T. The nature, functions, and origins of worry. 1994. [Google Scholar]
  • 17.Carey EA, de Bolger AdP, Wootton BMJJoO-C, Disorders R. Psychometric properties of the hoarding disorder-dimensional scale. 2019;21:91–6. [Google Scholar]
  • 18.Cheyne JE, de Bolger AdP, Wootton BMJJoo-c, disorders r. Reliability and validity of the Trichotillomania Dimensional Scale (TTM-D). 2018;19:61–5. [Google Scholar]
  • 19.Macfarlane F, Luo A, Moses K, Russell A, Cheyne J, de Bolger ADP, et al. Psychometric properties of the body dysmorphic disorder‐dimensional scale. 2020;24(2):114–22. [Google Scholar]
  • 20.Russell A, Pozo de bolger A, Moses K, Luo A, Wootton BMJCP. Psychometric properties of the excoriation (skin‐picking disorder) dimensional scale. 2020;24(3):246–53. [Google Scholar]
  • 21.Spitzer RL, Kroenke K, Williams J, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of internal medicine. 2006;166(10):1092–7. doi: 10.1001/archinte.166.10.1092 [DOI] [PubMed] [Google Scholar]
  • 22.Beard C, Björgvinsson TJJoad Beyond generalized anxiety disorder: psychometric properties of the GAD-7 in a heterogeneous psychiatric sample. 2014;28(6):547–52. [DOI] [PubMed] [Google Scholar]
  • 23.Houck PR, Spiegel DA, Shear MK, Rucci PJD, anxiety. Reliability of the self‐report version of the panic disorder severity scale. 2002;15(4):183–5. [DOI] [PubMed] [Google Scholar]
  • 24.Rosseel YJJoss. Lavaan: An R package for structural equation modeling and more. Version 0.5–12 (BETA). 2012;48(2):1–36. [Google Scholar]
  • 25.Li C-HJBrm. Confirmatory factor analysis with ordinal data: Comparing robust maximum likelihood and diagonally weighted least squares. 2016;48:936–49. [DOI] [PubMed] [Google Scholar]
  • 26.Brown T. Confirmatory Factor Analysis for Applied Research Guilford New York. 2006. [Google Scholar]
  • 27.Steiger JHJPb. Tests for comparing elements of a correlation matrix. 1980;87(2):245. [Google Scholar]
  • 28.Dunn OJ, Clark VJJotASA. Correlation coefficients measured on the same individuals. 1969;64(325):366–77. [Google Scholar]
  • 29.Diedenhofen B, Musch JJPo. cocor: A comprehensive solution for the statistical comparison of correlations. 2015;10(4):e0121945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Cohen JJPb. A power primer. 1992;112(1):155. [DOI] [PubMed] [Google Scholar]
  • 31.Koo TK, Li MYJJocm. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. 2016;15(2):155–63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Faul F, Erdfelder E, Lang A-G, Buchner AJBrm G* Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. 2007;39(2):175–91. [DOI] [PubMed] [Google Scholar]
  • 33.Terwee C, Mokkink L, Patrick DJC. COSMIN checklist with 4-point scale. 2011. [Google Scholar]
  • 34.Bujang MA, Baharum NJAoOS. A simplified guide to determination of sample size requirements for estimating the value of intraclass correlation coefficient: a review. 2017;12(1). [Google Scholar]
  • 35.Cheema JRJJoMASM. Some general guidelines for choosing missing data handling methods in educational research. 2014;13(2):3. [Google Scholar]
  • 36.Dugas MJ, Gagnon F, Ladouceur R, Freeston MHJBr, therapy. Generalized anxiety disorder: A preliminary test of a conceptual model. 1998;36(2):215–26. [DOI] [PubMed] [Google Scholar]
  • 37.Matsumoto D, Yoo SH, Fontaine JJJoc-cp. Mapping expressive differences around the world: The relationship between emotional display rules and individualism versus collectivism. 2008;39(1):55–74. [Google Scholar]
  • 38.Keefe JR, Chambless DL, Barber JP, Milrod BLJJopr. Treatment of anxiety and mood comorbidities in cognitive-behavioral and psychodynamic therapies for panic disorder. 2019;114:34–40. [DOI] [PubMed] [Google Scholar]
  • 39.Statistics. ABo. Labour force, Australia. 2020. [Available from: https://www.abs.gov.au/statistics/labour/employment-andunemployment/labour-force-australia/latest-release. [Google Scholar]
  • 40.Hinz A, Klein AM, Brähler E, Glaesmer H, Luck T, Riedel-Heller SG, et al. Psychometric evaluation of the Generalized Anxiety Disorder Screener GAD-7, based on a large German general population sample. 2017;210:338–44. [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Yann Benetreau

1 Jul 2022

PONE-D-21-36347

Psychometric properties of the Generalised Anxiety Disorder Dimensional Scale in an Australian sample

PLOS ONE

Dear Dr. Moses,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

In particular, please address the methodological comments raised by reviewer 1.

Please submit your revised manuscript by Aug 12 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Yann Benetreau, PhD

Division Editor (Staff Editor)

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

3. We note that your Data Availability statement states the following: "Data cannot be shared publicly because it remains under use by students and staff of the Western Sydney University."

PLOS journals require that all data presented in the study be made publicly available at or before the time of publication. If there are legal or ethical restrictions on the data being made publicly available, such as IRB restriction or patient confidentiality, authors must provide a way for fellow researchers to access the data.

Before we can proceed, please clarify the following:

a. Are there legal or ethical restrictions being placed upon the data? If so, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.).

b. If there are no legal or ethical restrictions, please upload the data as a Supporting Information file or to a recommended stable public repository. (https://journals.plos.org/plosone/s/recommended-repositories)

c. Please note that PLOS does not allow authors to be the sole contact for data inquiries. If the data is only available upon request, please provide contact information, such as an email address, for a non-author, institutional point of contact (such as an IRB or ethics committee contact) who can field data inquiries from fellow researchers. If the data contact is an individual, please provide their title and relationship to the data as well.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: No

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Psychometric properties of the Generalised Anxiety Disorder Dimensional Scale in an Australian sample

1- Introduction: It is very long, tedious and contains unnecessary information.

2- This questionnaire assess Anxiety Disorder but there is no mention of having psychiatric disorders, taking certain medications, etc. in patients. Only demographic characteristic has been presented.

3- Willing to participation is not as inclusion criteria

4- In construct validity, why Exploratory Factor Analysis (EFA) was not done?

5- Discriminate validity indicates how well an instrument differentiates between different groups who differ in some characteristics. In this study in abstract, there is divergent and in manuscript is discriminate validity. "The correlation between the GAD-D and GAD-7 was significantly greater than the correlation between the GAD-D and PDSS-SR, z(290) = 4.79 (p < .001, two-tailed), providing evidence for discriminate validity". What is the meaning of authors of z(290) = 4.79? Is that correlation between GAD-D and PDSS-SR?

6- The manuscript repeatedly mentions Part 1 and 2 and Time 1 and 2. If time 1 and 2 referred to test retest time reliability, what is the meaning of parts 1 and 2?

7- The interval time for assess test retest reliability is not mentioned.

8- The manner of the method section is chaotic.

9- It's mention that" The time between completion of Part 1 and Part 2 was not controlled or monitored". Why? This is very important and critical.

Reviewer #2: ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Jun 6;18(6):e0286634. doi: 10.1371/journal.pone.0286634.r002

Author response to Decision Letter 0


14 Sep 2022

Reviewer 1

1- Introduction: It is very long, tedious and contains unnecessary information.

The authors thank the reviewer for this feedback. The introduction has now been revised to increase succinctness and clarity. Please see pages 3-5 of the manuscript.

2- This questionnaire assess Anxiety Disorder but there is no mention of having psychiatric disorders, taking certain medications, etc. in patients. Only demographic characteristic has been presented.

The authors thank the reviewer for this feedback. As a non-clinical community sample has been utilised, psychiatric history was not sought from participants. This has now been clearly referenced. Please see page 6 of the manuscript.

3- Willing to participation is not as inclusion criteria

The authors thank the reviewer for this feedback. The authors have reviewed the manuscript to ensure that willingness to participate has not been included as an inclusion criteria.

4- In construct validity, why Exploratory Factor Analysis (EFA) was not done?

The authors thank the reviewer for this query. Given previous psychometric evaluations of the DSM 5 Dimensional Scales internationally, confirmatory factor analysis was deemed most appropriate to undertake in this study. Importantly, this approach is also consistent with existing literature, including Lebeau et al., 2012, Beesdo-Baum et al., 2012, Macfarlane et al., 2020 and Russell et al., 2020. This has now also been referenced in the manuscript. Please see page 7.

5- Discriminate validity indicates how well an instrument differentiates between different groups who differ in some characteristics. In this study in abstract, there is divergent and in manuscript is discriminate validity. "The correlation between the GAD-D and GAD-7 was significantly greater than the correlation between the GAD-D and PDSS-SR, z(290) = 4.79 (p < .001, two-tailed), providing evidence for discriminate validity". What is the meaning of authors of z(290) = 4.79? Is that correlation between GAD-D and PDSS-SR?

The authors thank the reviewer for this observation. Incorrect reference to divergent validity has now been removed. Please see page 2 of the manuscript.

6- The manuscript repeatedly mentions Part 1 and 2 and Time 1 and 2. If time 1 and 2 referred to test retest time reliability, what is the meaning of parts 1 and 2?

The authors thank the reviewer for this observation. All references to Time 1 and Time 2 have now been changed to Part 1 and Part 2 respectively. This has been changed throughout the manuscript, highlighted in red.

7- The interval time for assess test-retest reliability is not mentioned.

This has now been included. Please see page 7 of the manuscript.

8- The manner of the method section is chaotic.

The authors thank the reviewer for this feedback. The method section has now been revised. Please see pages 5-8 of the manuscript.

9- It's mention that" The time between completion of Part 1 and Part 2 was not controlled or monitored". Why? This is very important and critical.

The authors thank the reviewer for this feedback. Whilst completion time between Part 1 and Part 2 was monitored, it was not strictly adhered to by participants. This section has been reworded for clarity. Please see page 14 of the manuscript.

Reviewer 2

N/A

Attachment

Submitted filename: GAD-D Response to reviewers_FINAL .docx

Decision Letter 1

Alejandro Vega-Muñoz

23 Feb 2023

PONE-D-21-36347R1Psychometric properties of the Generalised Anxiety Disorder Dimensional Scale in an Australian samplePLOS ONE

Dear Dr. Moses,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Apr 09 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Alejandro Vega-Muñoz, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #3: (No Response)

Reviewer #4: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #3: Partly

Reviewer #4: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #3: Yes

Reviewer #4: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #3: No

Reviewer #4: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #3: Yes

Reviewer #4: No

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #3: I consider this to be a valuable article that presents the psychometric properties of the Generalised Anxiety Disorder Dimensional Scale in an Australian cummunity sample. However, there are a couple of issues to be improved that could help make the manuscript more comprehensive. These topics are described below.

Abstract

“A sample of 293 Australians (72.7% female) aged between 18 and 73 (M = 28.31 years; SD = 12.11 years) were recruited.” a sample was…?

Introduction

1.“The number of participants required for the study was based on the recommendation of

Tabachnick and Fidell(32), who specified that a minimum of 300 participants is adequate for a

psychometric analysis that includes examination of factor structure.”

I believe the authors could provide more information on the sample size planning procedure. Not just indicate a defined number for the sample. For example, see Kelley, K., & Lai, K. (2018). Confirmatory factor models: Power and accuracy for effects of interest. The Wiley handbook of psychometric testing: A multidisciplinary reference on survey, scale and test development, 113-139.

2. “This resulted in a final sample of 293(< 300) participants.” The final sample is smaller than initially proposed.

Methods

1. p.8, about the Generalised anxiety disorder dimensional scale “Cronbach’s α in the present study was .94.” I believe this should be reported in the results

Results

It is not explicitly stated in the manuscript whether the analyzed data are available in any public repository. If not, it would be ideal if the authors would do so.

Discussion

1.p.13 “To the author’s knowledge,…” to the authors' knowledge?

2. “Therefore, future studies evaluating the psychometric properties of the GAD-D should attempt to exceed the minimum 300 participants specified by Tabachnick and Fidell(32)” Again, I believe that the authors could make explicit a sampling procedure based on CFA, especially if the authors suggest that a higher n could guarantee a better model fit.

3. "This may suggest that avoidance and escape behaviours are typically observed in individuals that have GAD, despite their exclusion from the DSM-5 criteria. This would align particularly with models of GAD that highlight the maintaining role of avoidance; for example, those proposed by Borkovec (27) and Dugas et al.(42)" Interesting, future proposed research could add something to this point, considering the assessment (self-report) of avoidance and escape behaviors in clinical population having or not the GAD diagnosis.

4. “Notably, although all items demonstrated adequate factor loadings in the present study, items 9 and 10 had a notably lower loading onto the general factor than the other items of the scale.” Any of the expressions "notably" may be changed.

5. "...indicating that the present community sample had a similar or even greater level of GAD pathology than a sample of treatment-seeking individuals." It would not assert that it is GAD pathology if there is no clinical diagnosis to support it, but rather related symptoms or or anxiety problems.

6. "Future research should analyse the sensitivity and specificity of the GAD-D in an Australian sample to establish a cut-off point and allow Australian clinicians to also use the GAD-D as a screening tool". I believe that it should be emphasized that in order to achieve "cut-off points" it is necessary to include in the sample a properly diagnosed clinical population.

Reviewer #4: I congratulate authors for revising their manuscript. Manuscript is well written. I have a few suggestions.

1. Authors should provide what methods they used for data collection. While authors have mentioned an online questionnaire was used, there is no mention of website or software used for online survey.

2. While 140 (48%) individuals expressed interest in completing Part 2, only 21 participants provided complete data for Part 2. Any specific reason for very small retention? Does authors sent any reminder to those who showed interest for participation in part 2?

3. Sample size for retest analysis is too small. I would suggest to follow-up with those who showed interest to participate in part 2. Alternatively, authors may conduct additionally survey, which include at least 5o subjects in retest survey.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #3: No

Reviewer #4: Yes: Shahnawaz Anwer

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Jun 6;18(6):e0286634. doi: 10.1371/journal.pone.0286634.r004

Author response to Decision Letter 1


4 Apr 2023

Response to Reviewers

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

- The reference list has now been reviewed for accuracy and completeness. One omitted reference from the reference list has now been added. Please see page 22 of the revised manuscript.

To the authors knowledge, no retracted articles have been included in this manuscript. Three new references have been added, relevant to reviewer requests. Please see page 22 of the revised manuscript.

Reviewer #3:

Abstract

“A sample of 293 Australians (72.7% female) aged between 18 and 73 (M = 28.31 years; SD = 12.11 years) were recruited.” a sample was…?

- The authors thank the reviewer for identifying this error. This has now been rephrased as follows: ‘A sample of 293 Australians (72.7% female) aged between 18 and 73 (M = 28.31 years; SD = 12.11 years) was recruited.’ Please see page 2 of the revised manuscript.

Introduction

1.“The number of participants required for the study was based on the recommendation of

Tabachnick and Fidell(32), who specified that a minimum of 300 participants is adequate for a

psychometric analysis that includes examination of factor structure.”

I believe the authors could provide more information on the sample size planning procedure. Not just indicate a defined number for the sample. For example, see Kelley, K., & Lai, K. (2018). Confirmatory factor models: Power and accuracy for effects of interest. The Wiley handbook of psychometric testing: A multidisciplinary reference on survey, scale and test development, 113-139.

- The authors thank the reviewer for this feedback. A sampling size procedure has now been listed in the manuscript, which suggests adequate sample size used. This is also consistent with COSMIN guidelines (Terwee et al., 2011). Please see page 9 of the revised manuscript.

2. “This resulted in a final sample of 293(< 300) participants.” The final sample is smaller than initially proposed.

- Given use of sampling procedure (as recommended above), sample is now considered within appropriate range.

Methods

1. p.8, about the Generalised anxiety disorder dimensional scale “Cronbach’s α in the present study was .94.” I believe this should be reported in the results

- The authors thank the reviewer for this feedback. This is now recorded in the results section only. Please see page 10 of the revised manuscript.

Results

It is not explicitly stated in the manuscript whether the analyzed data are available in any public repository. If not, it would be ideal if the authors would do so.

- The authors thank the reviewer for highlighting this omission. As the data used for this project was collected as part of a larger body of research still currently in use, data is not currently available in a public repository, though may be requested from the lead investigator. This has now been added to the manuscripts as follows: ‘Data is available from the lead investigator upon reasonable request. ‘ Please see page 7 of the revised manuscript.

Discussion

1.p.13 “To the author’s knowledge,…” to the authors' knowledge?

- For clarity of language, this has now been removed. Please see page 13 of the revised manuscript.

2. “Therefore, future studies evaluating the psychometric properties of the GAD-D should attempt to exceed the minimum 300 participants specified by Tabachnick and Fidell(32)” Again, I believe that the authors could make explicit a sampling procedure based on CFA, especially if the authors suggest that a higher n could guarantee a better model fit.

- The authors thank the reviewer again for this recommendation. A revised sampling procedure has now been included, which suggests sample utilised is within appropriate range. Please see page 9 of the revised manuscript.

3. "This may suggest that avoidance and escape behaviours are typically observed in individuals that have GAD, despite their exclusion from the DSM-5 criteria. This would align particularly with models of GAD that highlight the maintaining role of avoidance; for example, those proposed by Borkovec (27) and Dugas et al.(42)" Interesting, future proposed research could add something to this point, considering the assessment (self-report) of avoidance and escape behaviors in clinical population having or not the GAD diagnosis.

- Thank you for this observation. This has now been highlighted as an area of further research in the manuscript. Please see page 12 of the revised manuscript.

4. “Notably, although all items demonstrated adequate factor loadings in the present study, items 9 and 10 had a notably lower loading onto the general factor than the other items of the scale.” Any of the expressions "notably" may be changed.

- Thank you for this observation. Wording has now been changed to the following: ‘Notably, although all items demonstrated adequate factor loadings in the present study, items 9 and 10 had a lower loading onto the general factor than the other items of the scale.’ Please see page 12 of the revised manuscript.

5. "...indicating that the present community sample had a similar or even greater level of GAD pathology than a sample of treatment-seeking individuals." It would not assert that it is GAD pathology if there is no clinical diagnosis to support it, but rather related symptoms or or anxiety problems.

- The authors thank the reviewer for highlighting this important distinction. This has now been corrected in the manuscript as follows: ‘indicating that the present community sample had a similar or even greater level of GAD or other anxiety symptomology than a sample of treatment-seeking individuals.’ Please see page 15 of the revised manuscript.

6. "Future research should analyse the sensitivity and specificity of the GAD-D in an Australian sample to establish a cut-off point and allow Australian clinicians to also use the GAD-D as a screening tool". I believe that it should be emphasized that in order to achieve "cut-off points" it is necessary to include in the sample a properly diagnosed clinical population.

- The authors thank the reviewer for identifying this important point. This has now been reflected in the manuscript as follows: ‘Future research should analyse the sensitivity and specificity of the GAD-D in an Australian sample to establish a cut-off point and allow Australian clinicians to also use the GAD-D as a screening tool, using a clinical sample of individuals who have received diagnosis via structured interview.’ Please see page 16 of the revised manuscript.

Reviewer #4:

1. Authors should provide what methods they used for data collection. While authors have mentioned an online questionnaire was used, there is no mention of website or software used for online survey.

- The authors thank the reviewer for identifying this omission. This has now been included, as follows: ‘All data was collected via Qualtrics.’ Please see page 7 of the revised manuscript.

2. While 140 (48%) individuals expressed interest in completing Part 2, only 21 participants provided complete data for Part 2. Any specific reason for very small retention? Does authors sent any reminder to those who showed interest for participation in part 2?

- The authors thank the reviewer for this feedback. It has now been highlighted in the manuscript (results section) that only one follow up email was sent to participants. Please see pages 9 and 10 of the revised manuscript.

The following has now also been added to the discussion section: ‘This is likely due to only one follow up email being sent to participants who expressed interest in completing this part of the study ‘and ‘Future research may also wish to use more follow up emails to increase participation in Part 2.’ Please see pages 14 and 15 of the revised manuscript.

3. Sample size for retest analysis is too small. I would suggest to follow-up with those who showed interest to participate in part 2. Alternatively, authors may conduct additionally survey, which include at least 5o subjects in retest survey.

- The authors thank the reviewer for this feedback. We accept that the sample size for re-test analysis is small. Unfortunately, collecting further data is not a possibility. It is noted that some references indicate that our sample size is broadly within range. For example, with two observations per subject, an ICC greater than 0.5, an α of 0.05, and power of 0.80, 22 participants are required to estimate the value of ICC (Bujang, 2017). This has now been noted in the manuscript. However, given this, we emphasise that assessment of re-test reliability is preliminary in nature within the manuscript. Please see pages 9 and 15 of the revised manuscript.

Attachment

Submitted filename: Response to reviews v3 .docx

Decision Letter 2

Alejandro Vega-Muñoz

27 Apr 2023

PONE-D-21-36347R2Psychometric properties of the Generalised Anxiety Disorder Dimensional Scale in an Australian samplePLOS ONE

Dear Dr. Moses,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jun 11 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Alejandro Vega-Muñoz, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #3: All comments have been addressed

Reviewer #4: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #3: Yes

Reviewer #4: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #3: Yes

Reviewer #4: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #3: Yes

Reviewer #4: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #3: Yes

Reviewer #4: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #3: (No Response)

Reviewer #4: I congratulate authors for revising their manuscript incorporating the reviewer comments. However, I still have some minor comments as follow:

1. In the last paragraph of introduction section, author stated that "The following will be investigated: 1) factor structure; 2) reliability; and 3) convergent and discriminant". I think author should use a past tense rather using future tense.

2. It is hypothesized that the psychometric properties of this scale will be consistent with ...?

3. Please explain GAD-D before using abbreviation.

4. This use of this analysis is consistent with that used in the existing literature (16, 17, 30,..)? Please check this sentence

5. Please explain Little’s MCAR test?

6. More than 50% citations are 10 years older. Please replace some of them with more recent citations.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #3: No

Reviewer #4: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Jun 6;18(6):e0286634. doi: 10.1371/journal.pone.0286634.r006

Author response to Decision Letter 2


8 May 2023

Response to Reviewers

Reviewer #3: (No Response)

Reviewer #4: I congratulate authors for revising their manuscript incorporating the reviewer comments. However, I still have some minor comments as follow:

1. In the last paragraph of introduction section, author stated that "The following will be investigated: 1) factor structure; 2) reliability; and 3) convergent and discriminant". I think author should use a past tense rather using future tense.

The authors thank the reviewer for this observation. This has now been corrected as follows: ‘The following were investigated: 1) factor structure; 2) reliability; and 3) convergent and discriminant validity.’ Please see page 5 of the manuscript.

2. It is hypothesized that the psychometric properties of this scale will be consistent with ...?

The authors thank the reviewer for this feedback. This has now been corrected to as follows: ‘It was hypothesised that the psychometric properties of this scale will be consistent with previous evaluations (11, 13, 14, 16, 23) . Specifically, the GAD-D is expected to demonstrate a unidimensional factor structure, excellent internal consistency, good test-retest reliability, convergent and discriminant validity.’ Please see page 5 of the manuscript.

3. Please explain GAD-D before using abbreviation.

The authors thank the reviewer for this observation. This has now been corrected. Please see page 4 of the manuscript.

4. This use of this analysis is consistent with that used in the existing literature (16, 17, 30,..)? Please check this sentence

The authors thank the reviewer for this observation. This has now been corrected as follows: ‘The use of this analysis is consistent with that used in the existing literature (16, 17, 30, 31).’ Please see page 7 of the manuscript.

5. Please explain Little’s MCAR test?

The authors thank the reviewer for highlighting this omission. This has now been added as follows: ‘Little’s MCAR test, designed to test for patterns in missing data, indicated that the data was missing completely at random, χ2(720) = 678.01, p = .87.’ Please see page 9 of the manuscript.

6. More than 50% citations are 10 years older. Please replace some of them with more recent citations.

The authors thank the reviewer for highlighting this. Prior to this feedback, 42 references were included. Of these, 5 have been replaced with references within the last ten years, three have been removed and one has been added. This results in 40 references at this submission. Of these, 15 are 10 years or older, resulting in only 37.5% of references being 10 years or older. Please see page 17 of the manuscript.

Attachment

Submitted filename: PLOS One response to reviewers v3.docx

Decision Letter 3

Alejandro Vega-Muñoz

22 May 2023

Psychometric properties of the Generalised Anxiety Disorder Dimensional Scale in an Australian sample

PONE-D-21-36347R3

Dear Dr. Moses,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Alejandro Vega-Muñoz, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #4: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #4: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #4: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #4: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #4: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #4: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #4: No

**********

Acceptance letter

Alejandro Vega-Muñoz

29 May 2023

PONE-D-21-36347R3

Psychometric properties of the Generalised Anxiety Disorder Dimensional Scale in an Australian sample

Dear Dr. Moses:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Alejandro Vega-Muñoz

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Key statistical output.

    (DOCX)

    Attachment

    Submitted filename: GAD-D Response to reviewers_FINAL .docx

    Attachment

    Submitted filename: Response to reviews v3 .docx

    Attachment

    Submitted filename: PLOS One response to reviewers v3.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES